The price of Adc Therapeutics SA (NYSE: ADCT) closed at $4.41 in the last session, up 16.67% from day before closing price of $3.78. In other words, the price has increased by $+0.6300 from its previous closing price. On the day, 631164 shares were traded.
Ratios:
We take a closer look at ADCT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.73 and its Current Ratio is at 4.97.
On April 24, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $7 to $2.
On December 06, 2022, CapitalOne started tracking the stock assigning a Overweight rating and target price of $12.CapitalOne initiated its Overweight rating on December 06, 2022, with a $12 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADCT now has a Market Capitalization of 311.96M and an Enterprise Value of 157.74M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.23. Its current Enterprise Value per Revenue stands at 2.27 whereas that against EBITDA is -1.08.
Stock Price History:
Over the past 52 weeks, ADCT has reached a high of $6.04, while it has fallen to a 52-week low of $0.36. The 50-Day Moving Average of the stock is 3.6794, while the 200-Day Moving Average is calculated to be 1.8979.
Shares Statistics:
According to the various share statistics, ADCT traded on average about 857.80K shares per day over the past 3-months and 666.35k shares per day over the past 10 days. A total of 82.29M shares are outstanding, with a floating share count of 54.79M. Insiders hold about 33.61% of the company’s shares, while institutions hold 56.32% stake in the company. Shares short for ADCT as of Feb 29, 2024 were 868.84k with a Short Ratio of 1.01, compared to 2.93M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.08% and a Short% of Float of 1.94%.
Earnings Estimates
The company has 5 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.54 for the current quarter, with a high estimate of -$0.48 and a low estimate of -$0.66, while EPS last year was -$0.74. The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.45 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$1.72 and -$2.66 for the fiscal current year, implying an average EPS of -$2.1. EPS for the following year is -$1.71, with 4 analysts recommending between -$1.51 and -$1.95.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $18.4M. It ranges from a high estimate of $19M to a low estimate of $17.91M. As of the current estimate, Adc Therapeutics SA’s year-ago sales were $18.99M, an estimated decrease of -3.10% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $19.98M, a decrease of -51.90% less than the figure of -$3.10% in the same quarter last year. There is a high estimate of $21M for the next quarter, whereas the lowest estimate is $18.46M.
A total of 5 analysts have provided revenue estimates for ADCT’s current fiscal year. The highest revenue estimate was $87M, while the lowest revenue estimate was $74.93M, resulting in an average revenue estimate of $80.76M. In the same quarter a year ago, actual revenue was $69.56M, up 16.10% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $95.83M in the next fiscal year. The high estimate is $101.6M and the low estimate is $88.72M. The average revenue growth estimate for next year is up 18.70% from the average revenue estimate for this year.
